1-(1-金刚烷基)乙基胺盐酸盐

M2质子通道抑制剂
  • ≥99%
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
A118559-1g
1g 现货 Stock Image
A118559-5g
5g 现货 Stock Image
A118559-25g
25g 现货 Stock Image
A118559-100g
100g 现货 Stock Image
A118559-500g
500g 现货 Stock Image

基本描述

别名 盐酸左氧氟沙星 盐酸盐 | 1-金刚烷乙胺 盐酸盐 | α-甲基-1-金刚烷甲胺盐酸盐 | 盐酸金刚乙胺
英文别名 1-(1-Adamantyl)ethylamine hydrochloride, 99% | 1-(ADAMANTAN-1-YL)ETHAN-1-AMINE HYDROCHLORIDE | MLS002548886 | RIMANTADINE HYDROCHLORIDE (MART.) | Rimantadine hydrochloride [USAN:USP] | Rimantadine, HCl | 1-(1-Aminoethyl)adamantane HCl | Algirem | DTXCID30
规格或纯度 ≥99%
英文名称 1-(1-Adamantyl)ethylamine hydrochloride
生化机理 M2质子通道抑制剂。在体内抑制甲型流感病毒。与盐酸金刚烷胺相比,具有更高的血脑屏障通透性。口服具有活性。
运输条件 常规运输
备注 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。
产品介绍


Product Application:

1-(1-Adamantyl)ethylamine hydrochloride is indicated for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults (17 years and older).

AI解读

名称和识别符

PubChem SID 488182078
IUPAC Name 1-(1-adamantyl)ethanamine;hydrochloride
INCHI InChI=1S/C12H21N.ClH/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12;/h8-11H,2-7,13H2,1H3;1H
InChi Key OZBDFBJXRJWNAV-UHFFFAOYSA-N
Canonical SMILES CC(C12CC3CC(C1)CC(C3)C2)N.Cl
Isomeric SMILES CC(C12CC3CC(C1)CC(C3)C2)N.Cl
WGK Germany 3
RTECS AU4717000
分子量 215.77
Reaxy-Rn 3623918
Reaxys-RN link address https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=3623918&ln=

化学和物理性质

溶解性 Freely soluble in water.
熔点 375°C
分子量 215.760 g/mol
XLogP3
氢键供体数Hydrogen Bond Donor Count 2
氢键受体数Hydrogen Bond Acceptor Count 1
可旋转键计数Rotatable Bond Count 1
精确质量Exact Mass 215.144 Da
单同位素质量Monoisotopic Mass 215.144 Da
拓扑极表面积Topological Polar Surface Area 26.000 Ų
重原子数Heavy Atom Count 14
形式电荷Formal Charge 0
复杂度Complexity 180.000
同位素原子数Isotope Atom Count 0
定义的原子立体中心计数Defined Atom Stereocenter Count 0
未定义的原子立体中心计数Undefined Atom Stereocenter Count 1
定义的键立体中心计数Defined Bond Stereocenter Count 0
未定义的键立体中心计数Undefined Bond Stereocenter Count 0
所有立体化学键的总数The total count of all stereochemical bonds 0
共价键合单元计数Covalently-Bonded Unit Count 2

安全和危险性(GHS)

象形图 GHS07
信号词 Warning
危险声明

H315: 引起皮肤刺激

H319: 引起严重眼睛刺激

H335: 可能引起呼吸道刺激

H302: 吞食有害

预防措施声明

P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾

P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。

P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。

P302+P352: 如皮肤沾染:用水充分清洗。

P321: 特殊处理(请参阅此标签上的...)。

P405: 密闭存放

P501: 将内容物/容器处理到。。。

P264: 处理后要彻底洗手。

P271: 仅在室外或通风良好的地方使用。

P270: 使用本产品时,请勿进食、饮水或吸烟。

P304+P340: 如误吸入:将人转移到空气新鲜处,保持呼吸舒适体位。

P403+P233: 存放在通风良好的地方。保持容器密闭。

P362+P364: 脱掉沾污的衣服,清洗后方可重新使用。

P330: 漱口

P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。

P301+P317: 如果被吞咽:请寻求医疗帮助。

P337+P317: 如果眼睛刺激持续:寻求医疗帮助。

P332+P317: 如果出现皮肤刺激:请寻求医疗帮助。

P319: 如果你感到不适,请寻求医疗帮助。

WGK Germany 3
RTECS AU4717000
Reaxy-Rn 3623918
Reaxys-RN link address https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=3623918&ln=
Merck Index 8224
个人防护装备 dust mask type N95 (US), Eyeshields, Gloves

技术规格说明书

Purity(Titration by AgNO3) 98.5-101.5(%)
Appearance(A118559) White Powder or Crystals
Infrared spectrum Conforms to Structure
Solubility in hot H2O almost transparency

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到12个结果

批号(Lot Number) 证书类型 日期 货号
G2113060 分析证书 25-04-08 A118559
E1921074 分析证书 23-03-09 A118559
B2304074 分析证书 22-12-08 A118559
B2304092 分析证书 22-12-08 A118559
B2304093 分析证书 22-12-08 A118559
B2304094 分析证书 22-12-08 A118559
B2304095 分析证书 22-12-08 A118559
B2304097 分析证书 22-12-08 A118559
B2304098 分析证书 22-12-08 A118559
B2304099 分析证书 22-12-08 A118559
B2304116 分析证书 22-12-08 A118559
E2312091 分析证书 22-12-08 A118559

显示更多⌵

参考文献

1. Segovia M et al..  (2019)  Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation..  Cancer Cell,  35  (5): (767-781.e6).  [PMID:31085177]
2. G G U Rohde.  (2011-08-03)  [Influenza : clinical symptoms, diagnostics and therapy]..  Der Internist,  52  ((9)): (1047-1052).  [PMID:21809066]
3. Belen Puente,Esther Hernandez,Susana Perez,Luis Pablo,Esther Prieto,Maria Angeles Garcia,Miguel Angel Bregante.  (2011-11-15)  Determination of memantine in plasma and vitreous humour by HPLC with precolumn derivatization and fluorescence detection..  Journal of chromatographic science,  49  ((10)): (745-752).  [PMID:22080801]
4. Linh Tran,Sy Bing Choi,Belal O Al-Najjar,Muhammad Yusuf,Habibah A Wahab,Ly Le.  (2011-12-14)  Discovery of potential M2 channel inhibitors based on the amantadine scaffold via virtual screening and pharmacophore modeling..  Molecules (Basel, Switzerland),  16  ((12)): (10227-10255).  [PMID:22158591]
5. Sander A A Kooijmans,Danielle Senyschyn,Muguntha M Mezhiselvam,Julia Morizzi,Susan A Charman,Babette Weksler,Ignacio-Andres Romero,Pierre-Olivier Couraud,Joseph A Nicolazzo.  (2012-02-23)  The involvement of a Na⁺- and Cl⁻-dependent transporter in the brain uptake of amantadine and rimantadine..  Molecular pharmaceutics,  ((4)): (883-893).  [PMID:22352408]
6. Jonathan Hsu,Nancy Santesso,Reem Mustafa,Jan Brozek,Yao Long Chen,Jessica P Hopkins,Adrienne Cheung,Gayane Hovhannisyan,Liudmila Ivanova,Signe A Flottorp,Ingvil Saeterdal,Arthur D Wong,Jinhui Tian,Timothy M Uyeki,Elie A Akl,Pablo Alonso-Coello,Fiona Smaill,Holger J Schünemann.  (2012-03-01)  Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies..  Annals of internal medicine,  156  ((7)): (512-524).  [PMID:22371849]
7. Tijana Ivanovic,Rutger Rozendaal,Daniel L Floyd,Milos Popovic,Antoine M van Oijen,Stephen C Harrison.  (2012-03-14)  Kinetics of proton transport into influenza virions by the viral M2 channel..  PloS one,  ((3)): (e31566-e31566).  [PMID:22412838]
8. Loren B Andreas,Matthew T Eddy,James J Chou,Robert G Griffin.  (2012-04-07)  Magic-angle-spinning NMR of the drug resistant S31N M2 proton transporter from influenza A..  Journal of the American Chemical Society,  134  ((17)): (7215-7218).  [PMID:22480220]
9. Lora Simeonova,Galina Gegova,Angel S Galabov.  (2012-05-24)  Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A (H3N2) infection in mice..  Antiviral research,  95  ((2)): (172-181).  [PMID:22617756]
10. V A Shibnev,T M Garaev,M P Finogenova,E S Shevchenko,E I Burtseva.  (2012-07-21)  New adamantane derivatives can overcome resistance of influenza A(H1N1)pdm2009 and A(H3N2) viruses to remantadine..  Bulletin of experimental biology and medicine,  153  ((2)): (233-235).  [PMID:22816091]
11. Yuxin Zhang,Hujun Shen,Mingbo Zhang,Guohui Li.  (2013-01-05)  Exploring the proton conductance and drug resistance of BM2 channel through molecular dynamics simulations and free energy calculations at different pH conditions..  The journal of physical chemistry. B,  117  ((4)): (982-988).  [PMID:23286443]
12. Bo OuYang,Shiqi Xie,Marcelo J Berardi,Xinhao Zhao,Jyoti Dev,Wenjing Yu,Bing Sun,James J Chou.  (2013-06-07)  Unusual architecture of the p7 channel from hepatitis C virus..  Nature,  498  ((7455)): (521-525).  [PMID:23739335]
13. George Atiee,Kenneth Lasseter,Sharon Baughman,Amy McCullough,Phil Collis,Alan Hollister,Jaime Hernandez.  (2011-10-01)  Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans..  Journal of clinical pharmacology,  52  ((9)): (1410-1419).  [PMID:21960669]
14. Saumil Doshi,Laurie Kamimoto,Lyn Finelli,Alejandro Perez,Arthur Reingold,Ken Gershman,Kimberly Yousey-Hindes,Kathryn Arnold,Patricia Ryan,Ruth Lynfield,Craig Morin,Joan Baumbach,Emily B Hancock,Nancy M Bennett,Shelley Zansky,Ann Thomas,William Schaffner,Alicia M Fry.  (2011-10-21)  Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009..  The Journal of infectious diseases,  204  ((12)): (1848-1856).  [PMID:22013219]
15. Georgina Cirrincione-Dall,Barbara J Brennan,Rosa M Ballester-Sanchis,Mercidita T Navarro,Brian E Davies.  (2011-11-01)  Pharmacokinetics and safety of coadministered oseltamivir and rimantadine in healthy volunteers: an open-label, multiple-dose, randomized, crossover study..  Journal of clinical pharmacology,  52  ((8)): (1255-1264).  [PMID:22039289]
16. Rafal M Pielak,Kirill Oxenoid,James J Chou.  (2011-11-15)  Structural investigation of rimantadine inhibition of the AM2-BM2 chimera channel of influenza viruses..  Structure (London, England : 1993),  19  ((11)): (1655-1663).  [PMID:22078564]
17. Mona Alqazzaz,Andrew J Thompson,Kerry L Price,Hans-Georg Breitinger,Sarah C R Lummis.  (2012-01-03)  Cys-loop receptor channel blockers also block GLIC..  Biophysical journal,  101  ((12)): (2912-2918).  [PMID:22208189]
18. Suelen F Sucena,Raphael E F Paiva,Camilla Abbehausen,Ives B Mattos,Marcelo Lancellotti,André L B Formiga,Pedro P Corbi.  (2012-01-20)  Chemical, spectroscopic characterization, DFT studies and antibacterial activities in vitro of a new gold(I) complex with rimantadine..  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy,  89  (114-118).  [PMID:22257715]
19. Márcia G Alves Galvão,Marilene Augusta Rocha Crispino Santos,Antonio Jl Alves da Cunha.  (2012-01-20)  Amantadine and rimantadine for influenza A in children and the elderly..  The Cochrane database of systematic reviews,  (CD002745-CD002745).  [PMID:22258950]
20. Guang-Quan Wang,Yan-Fang Qin,Li-Ming Du,Jun-Fei Li,Xu Jing,Yin-Xia Chang,Hao Wu.  (2012-09-11)  Determination of amantadine and rimantadine using a sensitive fluorescent probe..  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy,  98  (275-281).  [PMID:22959366]
21. Loren B Andreas,Alexander B Barnes,Björn Corzilius,James J Chou,Eric A Miller,Marc Caporini,Melanie Rosay,Robert G Griffin.  (2013-03-14)  Dynamic nuclear polarization study of inhibitor binding to the M2(18-60) proton transporter from influenza A..  Biochemistry,  52  ((16)): (2774-2782).  [PMID:23480101]

溶液计算器